AbbVie (ABBV) Gross Margin (2012 - 2026)

AbbVie (ABBV) has reported Gross Margin for 15 consecutive years, with 74.74% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin rose 292.0% year-over-year to 74.74% in Q2 2026; TTM through Jun 2026 was 71.48%, a 55.0% increase from a year earlier, with the FY2025 full-year figure at 70.24%, up 24.0% from the prior year.
• Gross Margin was 74.74% for Q2 2026 at AbbVie, up from 71.88% in the prior quarter.
• Over five years, Gross Margin peaked at 74.74% in Q2 2026 and troughed at 53.44% in Q3 2023.
• A 5-year average of 68.74% and a median of 70.47% in 2022 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin plunged 1266 bps in 2023 and surged 1744 bps in 2024, its largest moves.
• Over 5 years, Gross Margin stood at 72.42% in 2022, then decreased by 17 bps to 60.11% in 2023, then grew by 18 bps to 70.89% in 2024, then rose by 2 bps to 72.61% in 2025, then increased by 3 bps to 74.74% in 2026.
• The last three Gross Margin figures came in at 74.74% (Q2 2026), 71.88% (Q1 2026), and 72.61% (Q4 2025), per Business Quant data.